

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE
CONTROLLED SUBSTANCES BOARD

AFFIRMATIVE ACTION ORDER OF THE
CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On September 29, 2017, the United States Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register removing naldemedine from the schedules of the federal Controlled Substances Act. The scheduling action is effective September 29, 2017.
2. The Controlled Substances Board did not receive an objection to similarly removing naldemedine from the schedules under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order removing naldemedine as a controlled substance.
3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.16 and omitting the notice of proposed rule making, excluding naldemedine as a controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats naldemedine under chapter 961, Stats. by creating the following:

CSB 2.58 Exclusion of naldemedine. Section 961.16 (2) (a) (intro), Stats., is amended to read:
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrophan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:

This order shall take effect on November 20, 2017 to allow for publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated November 10, 2017



Doug Englebert, Chair
Controlled Substances Board